Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 5 July 2025
2020-02-19 14:35:00 Wednesday ET
The U.S. bank oligarchy has become bigger, more profitable, and more resistant to public regulation after the global financial crisis. Simon Johnson and
2025-07-12 11:35:00 Saturday ET
Mitch Anthony explains why it is now more important for top sales leaders to apply social skills and emotional competences to fulfill customer needs, wants,
2019-08-09 18:35:00 Friday ET
Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o
2019-03-19 12:35:00 Tuesday ET
U.S. tech titans increasingly hire PhD economists to help solve business problems. These key tech titans include Facebook, Amazon, Microsoft, Google, Apple,
2018-03-09 08:33:00 Friday ET
David Solomon succeeds Lloyd Blankfein as the new CEO of Goldman Sachs. Unlike his predecessors Lloyd Blankfein and Gary Cohn, Solomon has been an investmen
2020-11-17 08:27:00 Tuesday ET
Management consultants can build sustainable trust-driven client relations through the accelerant curve of business value creation. Alan Weiss (2016)